A genetic mutation causes increased serum levels of prothrombin (Factor II), which increases the risk of venous thrombosis.

A genetic mutation causes increased serum levels of prothrombin (Factor II), which increases the risk of venous thrombosis.

(See also hrombotische diseases at a glance.) A genetic mutation causes increased serum levels of prothrombin (Factor II), which increases the risk of venous thrombosis. Prothrombin (factor II) is a vitamin K-dependent precursor of thrombin, the final product of the coagulation cascade. The mutation of the prothrombin 20210 gene leads to increased prothrombin (with potentially increased thrombin generation, thus reducing the risk of venous thrombosis increases. The prevalence of mutations is dependent on the population studied between <1% to 6.5%. Scheme of blood coagulation. the diagnosis is made on the basis of genetic analysis of the prothrombin 20210 gene using blood samples. anticoagulation therapy with anticoagulation A parenteral heparin or low molecular weight heparin, followed by oral warfarin, in venous thrombo se or prophylaxis for patients at increased risk of thrombosis (eg. As used by immobilization, serious injury, surgery). It is not known if the newer oral anticoagulants, either thrombin (dabigatran) or factor Xa (z. B. rivaroxaban, apixaban) inhibit can be used for this disorder instead of other anticoagulants.

Comments

Leave a Reply

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.